USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial

UroGen Pharma files patent infringement action against Teva Pharmaceuticals

Max CMD Abhay Soi is new president of NATHEALTH

New leadership team announced at NATHEALTH Annual General Meeting 2024

EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia

Alembic Pharmaceuticals appoints Manish Kejriwal as Independent Director

AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer

Application based on results from the TROPION-Breast01 Phase III trial

Bio-Techne partners with Nikon Instruments for innovative spatial biology services

Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities

FDA Granted ODD to Utidelone Injectable from Biostar Pharma for treatment of breast cancer brain metastasis

Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux

Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide

The company had earlier announced about the approval received from the MHRA for Liraglutide

Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations